Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar:87:138.e7-138.e14.
doi: 10.1016/j.neurobiolaging.2019.09.007. Epub 2019 Sep 24.

Mitonuclear interactions influence Alzheimer's disease risk

Affiliations

Mitonuclear interactions influence Alzheimer's disease risk

Shea J Andrews et al. Neurobiol Aging. 2020 Mar.

Abstract

We examined the associations between mitochondrial DNA haplogroups (MT-hgs; mitochondrial haplotype groups defined by a specific combination of single nucleotide polymorphisms labeled as letters running from A to Z) and their interactions with a polygenic risk score composed of nuclear-encoded mitochondrial genes (nMT-PRS) with risk of dementia and age of onset (AOO) of dementia. MT-hg K (Odds ratio [OR]: 2.03 [95% CI: 1.04, 3.97]) and a 1 SD larger nMT-PRS (OR: 2.2 [95% CI: 1.68, 2.86]) were associated with elevated odds of dementia. Significant antagonistic interactions between the nMT-PRS and MT-hg K (OR: 0.45 [95% CI: 0.22, 0.9]) and MT-hg T (OR: 0.22 [95% CI: 0.1, 0.49]) were observed. Individual MT-hgs were not associated with AOO; however, a significant antagonistic interactions was observed between the nMT-PRS and MT-hg T (Hazard ratio: 0.62 [95% CI: 0.42, 0.91]) and a synergistic interaction between the nMT-PRS and MT-hg V (Hazard ratio: 2.28 [95% CI: 1.19, 4.35]). These results suggest that MT-hgs influence dementia risk and that variants in the nuclear and mitochondrial genome interact to influence the AOO of dementia.

Keywords: Alzheimer's disease; Mitochondria; Polygenic risk score.

PubMed Disclaimer

References

    1. Bender R, Lange S, 2001. Adjusting for multiple testing-when and how? J. Clin. Epidemiol 54, 343–349. - PubMed
    1. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR, 2013. Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci 14, 365–376. - PubMed
    1. Calvo SE, Clauser KR, Mootha VK, 2016. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res. 44, D1251–D1257. - PMC - PubMed
    1. Canevelli M, Grande G, Lacorte E, Quarchioni E, Cesari M, Mariani C, Bruno G, Vanacore N, 2016. Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta-analysis. J. Am. Med. Dir. Assoc 17, 943–948. - PubMed
    1. Carrieri G, Bonafè M, De Luca M, Rose G, Varcasia O, Bruni A, Maletta R, Nacmias B, Sorbi S, Corsonello F, Feraco E, Andreev KF, Yashin AI, Franceschi C, De Benedictis G, 2001. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer’s disease. Hum. Genet 108, 194–198. - PubMed

Publication types

Substances